Patents Assigned to ONCOIMMUNE INC.
  • USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS
    Publication number: 20190307841
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 10, 2019
    Applicant: OncoImmune, Inc.
    Inventors: Yang LIU, Pan Zheng
  • CD80 and CD86 Binding Protein Compositions and Uses Thereof
    Publication number: 20190263889
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Application
    Filed: September 19, 2017
    Publication date: August 29, 2019
    Applicants: ONCOIMMUNE, INC., CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
  • USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
    Publication number: 20190255140
    Abstract: The present invention relates to treating, a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIT inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIE inhibitor.
    Type: Application
    Filed: March 6, 2019
    Publication date: August 22, 2019
    Applicant: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Use of CD24 for lowering low-density lipoprotein cholesterol levels
    Patent number: 10369197
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: August 6, 2019
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Pan Zheng
  • Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereof
    Publication number: 20190127468
    Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
    Type: Application
    Filed: December 14, 2016
    Publication date: May 2, 2019
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • Use of CD24 Proteins for Treating Leptin-Deficient Conditions
    Publication number: 20190038716
    Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 7, 2019
    Applicant: ONCOIMMUNE, INC.
    Inventors: Yang LIU, Pan ZHENG, Martin DEVENPORT
  • USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
    Publication number: 20180177841
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 28, 2018
    Applicant: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS
    Publication number: 20180110828
    Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
    Type: Application
    Filed: May 6, 2016
    Publication date: April 26, 2018
    Applicant: OncoImmune, Inc.
    Inventors: Yang LIU, Pan ZHENG
  • Uses of hypoxia-inducible factor inhibitors
    Patent number: 9877998
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: January 30, 2018
    Assignee: ONCOIMMUNE, INC.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Uses of hypoxia-inducible factor inhibitors
    Patent number: 9427413
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: August 30, 2016
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 8895022
    Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: November 25, 2014
    Assignee: OncoImmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • Methods of use of soluble CD24 for therapy of rheumatoid arthritis
    Patent number: 8808697
    Abstract: Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: August 19, 2014
    Assignee: Oncoimmune, Inc.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
    Publication number: 20130136739
    Abstract: Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 30, 2013
    Applicant: ONCOIMMUNE, INC.
    Inventors: Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
  • USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
    Publication number: 20120264697
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia- Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Application
    Filed: June 25, 2010
    Publication date: October 18, 2012
    Applicant: ONCOIMMUNE INC.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng